MARKET

TVGNW

TVGNW

Tevogen Bio
NASDAQ
0.0290
-0.0024
-7.64%
Opening 13:05 03/31 EDT
OPEN
0.0309
PREV CLOSE
0.0314
HIGH
0.0340
LOW
0.0258
VOLUME
110.20K
TURNOVER
--
52 WEEK HIGH
0.0800
52 WEEK LOW
0.0253
MARKET CAP
--
P/E (TTM)
-0.0027
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TVGNW last week (0323-0327)?
Weekly Report · 1d ago
TEVOGEN BIO HOLDINGS: OPPORTUNITY EXPECTED TO CONTRIBUTE MORE THAN $20 MLN IN ANNUAL REVENUE WHILE SUPPORTING DOUBLE-DIGIT GROWTH BEGINNING NEXT YEAR
Reuters · 5d ago
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
Barchart · 5d ago
Tevogen Bio implements 1-for-50 reverse stock split; Nasdaq bid-price compliance returns
Reuters · 5d ago
TEVOGEN REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
Reuters · 5d ago
Weekly Report: what happened at TVGNW last week (0316-0320)?
Weekly Report · 03/23 09:44
Tevogen CIO Mittul Mehta to Speak at Microsoft Fabric Community Conference FabCon 2026
Reuters · 03/18 16:22
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
Barchart · 03/18 11:22
More
About TVGNW
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.

Webull offers Tevogen Bio Holdings Inc stock information, including NASDAQ: TVGNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVGNW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVGNW stock methods without spending real money on the virtual paper trading platform.